Table 1

Comparison between K562 Gleevec-treated group versus K562 control group.

A. K562 Gleevec-treated group versus K562 control group


Function

Enrichment Score

Enrichment p-value

# genes in list, in group


KEGG JAK STAT SIGNALING PATHWAY

12.616000

0.000003

8


ST STAT3 PATHWAY

6.219490

0.001990

2


B. JAK-STAT Signaling Pathway


Gene Symbol

Definition

p-value(K562 Treated vs. K562 Control)

Fold-Change

(K562 Treated vs. K562 Control)


BCL2L1

Homo sapiens BCL2-like 1 (BCL2L1), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA.

0.000076

-2.336810


CISH

Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA.

0.000754

-2.926860


CCND1

Homo sapiens cyclin D1 (CCND1), mRNA.

0.000964

-9.480380


SPRED1

Homo sapiens sprouty-related, EVH1 domain containing 1 (SPRED1), mRNA.

0.001425

-3.138930


SOCS1

Homo sapiens suppressor of cytokine signaling 1 (SOCS1), mRNA.

0.003518

-2.455500


IL6

Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA.

0.004541

-2.036640


PIK3CG

Homo sapiens phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG), mRNA.

0.005740

-2.292180


PIM1

Homo sapiens pim-1 oncogene (PIM1), mRNA.

0.006760

-2.343000


(a) Gene set analysis showing enrichment of gene sets under JAK/STAT pathway. These gene sets showed the number of genes that are downregulated in this pathway in K562 Gleevec-treated cells. (b) List of downregulated genes related to JAK/STAT pathway in K562 Gleevec-treated cells

Chai et al. BMC Cancer 2011 11:512   doi:10.1186/1471-2407-11-512

Open Data